Search results
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Investor's Business Daily· 1 day agoThe Swiss drugmaker's success has caught Big Pharma's attention, sparking an M&A spree that sent...
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional...
Morningstar· 3 days agoXTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer ...
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 3 days agoA phase III registrational study is expected to begin in 2025. For the acquisition, AstraZeneca...
Rakovina Therapeutics: AI a “paradigm shift” for cancer drug development
Proactive Investors· 2 days agoTeaming up with Dr. Artem Cherkasov from the University of British Columbia, Rakovina gained...
Novartis bags paediatric FDA label expansion for Lutathera
Pharmaceutical Technology via Yahoo Finance· 2 days agoIt is being evaluated as a treatment for metastatic castration-resistant prostate cancer (mCRPC) in...
Vets exposed to Agent Orange at US bases denied VA compensation
USA Today· 3 hours agoMounting evidence shows that as far back as the 1950s, in an effort to kill the ubiquitous poison...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 4 days agoHyundai Bioscience announces its successful result from a preclinical study of a Niclosamide-based oral anticancer drug to treat triple-negative breast cancer< ...
20 Countries with the Highest Cancer Survival Rates in the World
Insider Monkey via Yahoo Finance· 7 days agoIn this article, we will be taking a look at the 20 countries with the highest cancer survival rates...
Novartis raises forecasts as top drug sales beat Wall Street estimates
BioPharma Dive via Yahoo Finance· 3 days agoThe company now says it has updated data that will support an approval application for Pluvicto’s...
PSA Detectable After Radical Prostatectomy
Medscape· 3 days agoFollowing radical prostatectomy, however, approximately 20%-40% of patients with localized disease will experience biochemical recurrence.